QCM
PCVX icon

Qsemble Capital Management’s Vaxcyte PCVX Stock Holding History

Qsemble Capital Management’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6,701
Closed -$309K – 577
2025
Q4 		$309K Buy
6,701
+355
+6% +$15.9K 0.03% 433
2025
Q3 		$229K Sell
6,346
-2,977
-32% -$98.6K 0.02% 426
2025
Q2 		$303K Buy
+9,323
New +$306K 0.03% 369
2025
Q1 		– Sell
-3,840
Closed -$314K – 545
2024
Q4 		$314K Buy
+3,840
New +$381K 0.04% 327

Other funds holding PCVX

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Qsemble Capital Management's PCVX Position: Q1 2026 in Review

Qsemble Capital Management sold out of Vaxcyte (PCVX) in Q1 2026, closing a stake of 6,701 shares — an estimated $309K sold.

Qsemble Capital Management first reported a position in PCVX in Q4 2024 and held it in 4 quarters. The position peaked at $314K in Q4 2024. 336 funds tracked by Wall St. Rank hold PCVX as of Q1 2026.

  • Qsemble Capital Management reported no remaining Vaxcyte position as of Q1 2026 after selling out during the quarter.
  • Qsemble Capital Management sold 6,701 Vaxcyte shares in Q1 2026, an estimated $309K.
  • Qsemble Capital Management first reported a position in Vaxcyte in Q4 2024 and held it in 4 quarters.
  • Qsemble Capital Management's Vaxcyte position peaked at $314K in Q4 2024.
  • 336 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2026.

Based on Qsemble Capital Management's 13F filing for Q1 2026, filed 7 May 2026.